Saturday 17 October 2026
Export VVOS’s income statement to Excel — free account
Vivos Therapeutics, Inc.
VVOS Healthcare Medical Devices
Vivos Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $17.4 million, up 16.0% from fiscal 2024. In the quarter to June 2026, revenue grew 34.9%, EPS grew 43.6%, free cash flow grew 16.4% and total debt rose 2.79%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.13
0.01
−7.14%
Follow VVOS
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 141.00 | 54.50 | 8.53 | 2.73 | 1.91 | 1.93 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 360.25 | 271.50 | 92.25 | 74.05 | 12.75 | 7.95 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 98 | 167 | 163 | 114 | 109 | 268 | ||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.13 | 0.10 | 0.10 | 0.12 | 0.14 | 0.07 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | 4 | 11 | 13 | 17 | 16 | 14 | 15 | 17 | ||||
| Gross margin, % | — | — | 55.37 | 75.99 | 79.70 | 74.65 | 62.52 | 59.93 | 60.00 | 60.44 | |||||
| EBT | — | — | (8) | (11) | (12) | (20) | (24) | (14) | (11) | (21) | |||||
| EBT margin, % | — | — | (222.54) | (94.39) | (92.28) | (120.15) | (148.81) | (98.42) | (74.09) | (121.71) | |||||
| Net income | — | 0 | (8) | (11) | (12) | (20) | (24) | (14) | (11) | (21) | |||||
| Depreciation | — | — | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 5.21 | 23.10 | 25.38 | 19.88 | 17.40 | 11.32 | 2.99 | 1.70 | ||||
| Earnings | — | — | (12.97) | (21.80) | (35.00) | (24.00) | (26.00) | (11.14) | (2.22) | (2.07) | |||||
| Cash flow | — | — | (7.45) | (10.83) | (11.03) | (18.53) | (21.27) | (9.80) | (2.53) | (1.49) | |||||
| Capex | — | — | 0.00 | (0.36) | (0.23) | (2.82) | (1.00) | (0.66) | (0.11) | (0.23) | |||||
| Free cash flow | — | — | (7.45) | (11.18) | (11.27) | (21.35) | (22.27) | (10.46) | (2.64) | (1.71) | |||||
| Book value | — | — | 7.55 | (5.97) | 32.86 | 30.07 | 5.21 | 0.34 | 1.58 | (0.15) | |||||
| Shares, m | — | — | 1 | 0 | 1 | 1 | 1 | 1 | 5 | 10 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | 8.76 | 8.76 | 5.82 | 2.83 | 1.06 | 1.04 | 1.43 | 1.20 | |||||
| P/B | — | — | 0.00 | 0.00 | 4.50 | 1.87 | 3.55 | 35.00 | 2.71 | 0.00 | |||||
| EV/Sales | — | — | 8.75 | 8.75 | 4.53 | 1.49 | 0.99 | 1.08 | 1.16 | 1.59 | |||||
| EV/FCF | — | — | (14.75) | (14.75) | (10.20) | (1.39) | (0.78) | (1.16) | (1.31) | (1.57) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (5) | (5) | (6) | (16) | (20) | (12) | (13) | (15) | ||||
| Capex | — | — | (1) | 0 | 0 | (2) | (1) | (1) | (1) | (2) | |||||
| Free cash flow | — | — | (5) | (6) | (6) | (18) | (21) | (13) | (13) | (18) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | 0 | (7) | 13 | 20 | (1) | (5) | 2 | (14) | ||||
| Total debt | — | — | 1 | 4 | 1 | 1 | 2 | — | — | 9 | |||||
| Net debt | — | — | (1) | 3 | (17) | (23) | (1) | (2) | (6) | 7 | |||||
| Shareholders’ equity | — | — | 5 | (3) | 17 | 26 | 5 | 0 | 8 | (2) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (230.11) | (149.21) | (109.42) | (68.75) | (100.59) | (111.11) | (85.62) | (104.71) | ||||
| ROIC | — | — | 0.00 | (2,225.84) | (752,500.00) | (459.22) | (423.39) | 0.00 | (412.15) | (237.15) | |||||
| ROE | — | — | (1,002.20) | (1,248.00) | (257.45) | (95.57) | (157.19) | (521.22) | (266.25) | (648.99) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Vivos Therapeutics, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| WOK WORK Medical Technology Group LTD | $6.0M | — | — | — | — | −948.94% (below 0%: shrinking) | — | — | Compare |
| AMIX Autonomix Medical, Inc. | $5.7M | — (loss-making) | — | — | n/m | −36.10% (below 0%: shrinking) | — | 0.00% | Compare |
| NVNO enVVeno Medical Corporation | $5.5M | — (loss-making) | — (loss-making) | +0.32% (above 0%: growing) | n/m | +4.60% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CODX Co-Diagnostics, Inc. | $5.3M | — (loss-making) | — (loss-making) | +1.96% (above 0%: growing) | n/m | +17.47% (above 0%: growing) | 72.73% | (3,733.17%) | Compare |
| TBIO Telesis Bio Inc. | $5.3M | — (loss-making) | — (loss-making) | −61.79% (below 0%: shrinking) | n/m | −17.96% (below 0%: shrinking) | 64.43% | (349.74%) | Compare |
| VNRX VolitionRX Limited | $5.3M | — (loss-making) | — (loss-making) | −1.97% (below 0%: shrinking) | n/m | +18.58% (above 0%: growing) | 100.00% | (1,042.39%) | Compare |
| TRIB Trinity Biotech PLC | $5.1M | — (loss-making) | — (loss-making) | +43.28% (above 0%: growing) | n/m | +75.24% (above 0%: growing) | 35.43% | (24.53%) | Compare |
| VVOS Vivos Therapeutics, Inc. | $4.8M | — (loss-making) | — (loss-making) | +34.90% (above 0%: growing) | n/m | +16.44% (above 0%: growing) | 57.31% | (93.63%) | |
| INBS Intelligent Bio Solutions Inc. | $4.8M | — (loss-making) | 5.4× | +51.10% (above 0%: growing) | n/m | −31.59% (below 0%: shrinking) | 43.23% | (360.19%) | Compare |
| Median of peers | $5.3M | — | — | +1.14% | — | −6.68% | 53.83% | (349.74%) |
Vivos Therapeutics, Inc. (VVOS) key facts
- Strength: Vivos Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $17.4 million, up 16.0% from fiscal 2024.
- Vivos Therapeutics, Inc. (VVOS) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, VVOS traded at $0.13, a market capitalization of $4.8 million.
- Return on equity was −649.0% and debt-to-equity -2.04.
- Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −9.08 (distress zone) for fiscal 2025.